Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2
et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542 (date from earlier preprint) (In Vitro)
, Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against.., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542 (date from earlier preprint) (In Vitro)
In Vitro study showing enhanced antiviral activity of ivermectin and remdesivir in combination.[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.3 In Vitro studies support the efficacy of remdesivir [De Forni, Delandre, Jeffreys].
1.
De Forni et al., PLoS ONE, doi:10.1371/journal.pone.0276751,
Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients,
https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0276751.
2.
Delandre et al., Pharmaceuticals, doi:10.3390/ph15040445,
Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants,
https://www.mdpi.com/1424-8247/15/4/445.
3.
Gérard et al., Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2145,
Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database,
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2145.
4.
Jeffreys et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542 (preprint 12/24/2020),
Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2,
https://www.sciencedirect.com/science/article/pii/S0924857922000309.
Jeffreys et al., 24 Dec 2020, peer-reviewed, 17 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: In vitro synergistic interaction of remdesivir and ivermectin against SARS-CoV-2
Editor: Dr Jim Gray
Journal Pre-proof
Remdesivir-ivermectin combination displays synergistic interaction
with improved in vitro activity against SARS-CoV-2
Laura N Jeffreys , Shaun H Pennington , Jack Duggan ,
Claire H Caygill , Rose C Lopeman , Alastair F Breen ,
Jessica B Jinks , Alison Ardrey , Samantha Donnellan ,
Edward I Patterson , Grant L Hughes , David W Hong ,
Paul M O’Neill , Ghaith Aljayyoussi , Andrew Owen ,
Stephen A Ward , Giancarlo A Biagini
PII:
DOI:
Reference:
S0924-8579(22)00030-9
https://doi.org/10.1016/j.ijantimicag.2022.106542
ANTAGE 106542
To appear in:
International Journal of Antimicrobial Agents
Received date:
Accepted date:
9 September 2021
20 January 2022
Please cite this article as: Laura N Jeffreys , Shaun H Pennington , Jack Duggan , Claire H Caygill ,
Rose C Lopeman , Alastair F Breen , Jessica B Jinks , Alison Ardrey , Samantha Donnellan ,
Edward I Patterson , Grant L Hughes , David W Hong , Paul M O’Neill , Ghaith Aljayyoussi ,
Andrew Owen , Stephen A Ward , Giancarlo A Biagini , Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2, International Journal
of Antimicrobial Agents (2022), doi: https://doi.org/10.1016/j.ijantimicag.2022.106542
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2022 Published by Elsevier Ltd.
FULL TITLE
Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro
activity against SARS-CoV-2
SHORT TITLE
In vitro synergistic interaction of remdesivir and ivermectin against SARS-CoV-2
AUTHORS
Laura N Jeffreys1*, Shaun H Pennington1*‡, Jack Duggan1, Claire H Caygill, Rose C
Lopeman, Alastair F Breen1, Jessica B Jinks1, Alison Ardrey1, Samantha Donnellan1, Edward
I Patterson1,2, Grant L Hughes1,2, David W Hong3, Paul M O’Neill3, Ghaith Aljayyoussi1,
Andrew Owen4, Stephen A Ward1 and Giancarlo A Biagini1*‡
1
Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool
School of Tropical Medicine, Liverpool, L3 5QA, UK
2
Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA,
UK
3
Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD, U.K.
4
Department of Pharmacology and Therapeutics, Centre of Excellence in Long-acting
Therapeutics (CELT), University of Liverpool, Liverpool, L69 3GE, UK.
1
*
JOINT FIRST AUTHORS
‡CO-CORRESPONDING AUTHORS
Giancarlo A Biagini
Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool
School of Tropical Medicine, Liverpool, L3 5QA, UK
+44151 705 3151
giancarlo.biagini@lstmed.ac.uk
Shaun H Pennington
Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool
School of Tropical Medicine, Liverpool, L3 5QA, UK
+44151 702 9427
shaun.pennington@lstmed.ac.uk
ABSTRACT WORD COUNT:
130
MAIN DOCUMENT WORD..
Loading..
jeffreys
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.